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1. Introduction 
1.1 Japanese herbal (Kampo) medicine in Japan 
Japanese Herbal (Kampo) Medicine, which is covered by national health insurance in Japan, 
is often prescribed in the primary care field, and is also applied as an alternative remedy for 
several gynecological diseases such as menstrual disorders, and menopausal symptoms. 
Since ancient times, a wide variety of Kampo formulae have been used traditionally and 
found to be clinically effective in gynecological diseases. These formulae usually contain 
components from several medicinal plants that are thought to exert estrogenic effects 
contributing to the effective treatment of menstrual disorders (1 – 6). The clinical use of 
traditional herbal medicines in menopausal women has previously been reported (7). 
1.2 Characteristics of Japanese herbal (Kampo) medicines 
Kampo Medicine has two features that differ from Western Medicine, i) the Kampo formula 
is composed of crude drugs, not purified chemical products; ii) the diagnostic system in 
Kampo Medicine is different from that in Western medicine. Kampo formulae are generally 
composed of several herbal components, therefore it is considered that these remedies are 
safe. However, pseudoaldosteronism caused by licorice root is a well known adverse effect 
(8), and there are also allergic effects, such as skin eruptions (9) and liver injury (10), that can 
be induced by crude preparations. It is also thought that Kampo diagnosis may not be easy 
for readers to understand. When we treat the patients with menstrual disorders with Kampo 
Medicine, it is necessary to establish a Kampo diagnosis as well as a diagnosis by Western 
medicine. This issue makes it difficult to perform controlled clinical trials. Therefore, there is 
very little evidence supporting the use of Kampo formulae for gynecological diseases, 
although Kampo formulae are often prescribed for gynecological diseases in Japan. 
In this chapter, we describe estrogen-like activities and clinical effects on menstrual disorders, 
as well as current topics concerning Kampo therapeutic strategy for menstrual disorders. 
2. Action on the hypothalamus-pituitary-ovarian system (HPO system) of 
herbal medicine 
Menstrual irregularity is an endocrinal disorder that is often observed in females of 
reproductive age. Many researchers have vigorously investigated the etiology and 
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pathogenesis of the menstrual irregularity and the pharmacological action of several agents, 
and as a result, the mechanisms underlying menstrual irregularity have been gradually 
clarified. Namely, menstrual cycle is regulated by the hypothalamic-pituitary-ovarian 
system (HPO system). Secretory dysfunction of the GnRH, FSH, LH and E2, as well as 
abnormalities of those receptor induce dysfunction of the HPO system, leading to menstrual 
irregularity, such as amenorrhea. 
It is thought that the therapeutic strategy of Western Medicine is not adequate to treat 
menstrual irregularity, even though variable regimens have been developed. Recently, it 
has been suggested that traditional herbs and Kampo formulae can influence the HPO 
system.  
2.1 Single herb 
2.1.1 Pueraria mirifica (a Thai herb) 
Pueraria mirifica (PM), a Thai herb, contains a large amount of phytoestrogens. Estrogen-
mimicking plant compounds, in its tuberous roots have been used as a rejuvenating drug 
in Thailand (11). However, the clinical effects of PM on lipid metabolism and the 
underlying molecular mechanisms remain undetermined. Previously, we examined the 
effects of PM on serum lipid parameters in a randomized, double-blind, placebo-
controlled clinical trial, because Impaired lipid metabolism is an important health 
problem in postmenopausal women with insufficient estrogen. After 2 months of 
treatment, the PM group showed a significant increase in serum concentrations of high-
density lipoprotein (HDL) cholesterol and apolipoprotein (apo) A-1 (34% and 40%, 
respectively), and a significant decrease in low-density lipoprotein (LDL) cholesterol and 
apo B (17% and 9%, respectively), compared with baseline measurements. Moreover, 
significant decreases were observed in the ratios of LDL cholesterol to HDL cholesterol 
(37%) and apo B to apo A-1 (35%). Recently, the effects of PM phytoestrogens on the 
activation of estrogen receptor (ER)-mediated transactivation have been determined by 
transient expression assays of a reporter gene in cultured cells. Among PM 
phytoestrogens, miroestrol and coumestrol enhance both ER┙- and ER┚-mediated 
transactivation, whereas other phytoestrogens, including daidzein and genistein, 
preferentially enhanced ER┚-mediated transactivation. Taken together, PM has a 
beneficial effect on lipid metabolism in postmenopausal women, which may result from 
the activation of gene transcription through selective binding of phytoestrogens to ER┙ 
and ER┚ (12). 
2.1.2 Vitex agnus castus (Japanese name: Seiyoninjinboku: Not a Kampo herb) 
Vitex is a deciduous shrub native to European, Mediterranean and Central Asian countries. 
In-vitro studies describe dopaminergic effects of Vitex via dose-dependent binding of 
dopamine-2 receptors, yielding potent inhibition of prolactin in cultured pituitary cells. The 
flavonoid apigenin can be isolated from Vitex and has selective binding affinity for the ┚-
estrogen receptor subtype (13). Human studies reported inhibition of FSH and stimulation 
of LH secretion and presumed the hormone modulation of FSH and LH affected the 
downstream hormones progesterone and estrogen (14, 15). Based on current 
pharmacological studies and RCTs, Vitex is indicated for hyperprolactinemia – related 
reproductive dysfunction (16). 
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2.1.3 Cinnamon bark (Japanese name: Keihi) 
Cinnamon bark is a major herb of the Kampo formulae: Keishibukuryogan and Tokikenchuto, 
which are indicated for several menstrual disorders. While several pharmacological studies 
have suggested anti-inflammatory properties, the mechanisms by which the herb exerts its 
various activities are not yet well understood. Cinnamaldehyde, a major active constituent 
of Cinnamomum cassia has been shown to stimulate cathecholamine release from the 
adrenal glands. On in-vitro analysis, exposure of human adrenal cells (H295R) to 
cinnamaldehyde increased progesterone release in a dose-dependent manner. In contrast, 
the release of cortisol or estradiol was not affected by treatment with cinnamaldehyde (17). 
Recent reports suggest menstrual distress is related to higher estradiol levels, higher 
estradiol/progesterone ratios (18). Therefore, these actions of cinnamaldehyde may be 
attributed to the clinical effects of Cinnamon bark. 
2.1.4 Cimicifuga racemosa (Japanese name: Shoma ) 
Extracts (ethanolic and isopropanolic aqueous, Remifemin) of the rootstock of the herb 
Cimicifuga racemosa (black cohosh) are active ingredients developed for the treatment of 
gynecologic disorders, particularly climacteric symptoms (19). Drug-monitoring and clinical 
studies documenting experience with Cimicifuga racemosa rootstock extracts have provided 
a database on the effect of this herbal treatment for menopausal symptoms (e.g., hot flashes, 
profuse sweating, sleep disturbances, depressive moods). These studies have shown good 
therapeutic efficacy and tolerability profiles of Cimicifuga. In addition, clinical and 
experimental investigations indicate that the rootstock of Cimicifuga racemosa does not 
show any hormone-like activity, as was originally postulated. 
2.1.5 Angelica sinensis (Japanese name: Toki) 
One of the most common applications for Angelica sinensis in the United States is for 
relief of vasomotor symptoms associated with menopause. Such symptoms include hot 
flashes, skin flushing, and increased perspiration. The mechanism of action, however, is 
still unclear. In a randomized, double-blind, placebo-controlled clinical trial, 71 
postmenopausal women received either Toki (4.5 g) or placebo daily for 24 weeks (20). 
There were no differences in vasomotor symptoms between the two groups, and there 
appeared to be no estrogen-like effects on vaginal epithelial tissue. The use of Toki alone 
can be criticized because traditional Herbal practitioners never prescribed it alone, but 
rather in combination with several other herbs. 
These observations are very interesting, because Kampo formulae are water extracts, 
sometimes caledl “decoction”, namely crude drug, which contains a great many ingredients. 
It is considered that the action of Kampo formula may be multi-targeted. A herbal mixture 
containing Angelica sinensis root, Paeonia lactiflora root, Ligusticum rhizome, Atractylodes 
rhizome, Alismatis rhizome, and Sclerotium poria has been reported to reduce menopausal 
disturbances, including vasomotor symptoms by about 70 percent (20, 21) 
2.2 Kampo formula: Several herb mixture 
2.2.1 Tokishakuyakusan (Chinese name, Dang gui shao yao san) 
Tokishakuyakusan (root of Angelica, peony root, cnidium rhizome, alisma rhizome, 
atractylodis rhizome, poria sclerotium) is a commonly prescribed Kampo formula for 
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menstrual irregularity or menopausal symptoms in woman. The action of this formula on 
HPO system has been analyzed in vitro and in several animal models. First, in the 
preovulatory follicles incubated in vitro, it has been demonstrated that Tokishakuyakusan 
stimulates preovulatory follicles before a LH surge to secrete progesterone, but 
Tokishakuyakusan suppresses E2 secretion by growing preovulatory follicles before the LH 
surge (22). However, in vivo, Tokishakuyakusan increases the concentrations of estradiol-17 
┚(E2), progesterone and testosterone (1, 23). These observations suggest that 
Tokishakuyakusan influences the HPO system. Recently, it has been reported that 
Tokishakuyakusan has an influence on the brain in the ovariectomized mice. Administration 
of Tokishakuyakusan significantly suppressed the decrease in choline acetyltransferase 
activity in the cerebral cortex and the dorsal hippocampus of the ovariectomized mice (24). 
These phenomena may explain the mechanism of action of Tokishakuyakusan on mood 
disturbance in human climacteric disorder. 
2.2.2 Keishibukuryogan (Chinese name, Gui zhi fu ling wan) 
Keishibukuryogan (bark of Cinnamomum cassia, root of Paeonia lactiflora, seed of Prunus 
persica or P. persiba var. davidiana, carpophores of Poria cocos, root bark of Paeonia 
suffruticosa) is a traditional herbal formula used in Kampo medicine in Japan. This remedy 
for menopausal symptoms has been approved by the Ministry of Health, Labor and Welfare 
in Japan. To date, there have been several studies demonstrating that Keishibukuryogan 
ameliorates menopausal hot flashes. The action of this formula on HPO system has also 
been analyzed in vitro and in several animal models.  
It has been reported that oral administration of Keishibukuryogan may act as a LH-
RH/GnRH antagonist and/or have a weak anti-estrogen effect in the rat model (25). 
However, Keishibukuryogan also increased the concentrations of E2, progesterone and 
testosterone, in vivo rat model (23). Recently, it has demonstrated that oral 
Keishibukuryogan administration did not affect the decreased concentration of plasma E2 
and decreased uterine weight caused by ovariectomy, although hormone replacement with 
E2 restored them, in ovariectomized rats (3). These findings suggest that Keishibukuryogan, 
which does not alter plasma levels of estrogen, may be useful for the treatment of hot flashes 
in patients for whom estrogen replacement therapy is contraindicated, as well as in 
menopausal women. 
Furthermore, Keishibukuryogan demonstrates several other activities such as effects on 
immunomodulation and microcirculation. Therefore, Keishibukuryogan is usually 
administered to the patients with gynecological disorders, as well as inflammatory 
diseases such as rheumatoid arthritis and disturbances of the peripheral circulation in 
Japan.  
2.2.3 Kamishoyosan (Chinese name, Jia wei xiao yao san) 
Kamishoyosan (Bupleurum root, root of Angelica, peony root, atractylodis rhizome, poria 
sclerotium, menthae herba, zingiberis rhizome, licorice root, moutan bark, gardenia fructus), 
a Kampo formula used to treat menopausal psychotic syndromes in women, consists of ten 
crude herbal preparations. The anxiolytic effect of Kamishoyosan has usually been 
investigated using the social interaction (SI) test in mice. Whether the effect of 
Kamishoyosan was due to the stimulating and/or sedating effects was examined by the 
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open field locomotion test (26). It appears the Kamishoyosan-induced SI behavior is due 
to its anxiolytic effect. The unaltered results of the open field test indicated that 
kamishoyosan was neither a stimulant nor sedative. Furthermore, Gardeniae Fructus in 
Kamishoyosan and geniposide (its ingredient) play a role in the anxiolytic effect of 
kamishoyosan. This formula may not be effective to ameliorate menstrual disorders, but 
for psychotic symptoms in women. 
2.2.4 Unkeito (Chinese name, Wen jing tang) 
From ancient times, Unkeito (Pinellia tuber, Ophiopogen tuber, root of Angelica, peony root, 
cnidium rhizome, Ginseng radix, bark of Cinnamomum cassia, Asini corii collas, Moutan 
bark, licorice root, zingiberis rhizome, Euodia fruit) is a representative formula for the 
treatment of menstrual disorders, and at present, this Kampo formula has usually been 
administered to the patients with menstrual irregularity. The action of Unkeito on the 
HPO system has been clarified by several researchers (27 – 29). In vitro analysis has also 
demonstrated that Unkeito stimulates the secretion of progesterone from the preovulatory 
follicles before the LH surge, but Keishibukuryogan suppresses E2 secretion by growing 
preovulatory follicles before a LH surge (22). To analyze the effect of Unkeito and its 
components on LH-RH/GnRH and LH release in an animal model, the mediobasal 
hypothalamus (MBH) alone or the pituitary alone or the pituitary in sequence with the 
MBH from normal female rats in diestrus was perfused in a sequential double-chamber 
perfusion system (30). These analyses demonstrated that Unkeito induces GnRH-induced 
LH release from the anterior pituitary and can be used for the treatment of patients with 
hypothalamic amenorrhea.  
3. The clinical efficacy of herbal medicine for menstrual irregularity 
As described, several herbs and Kampo formula have the potential to improve menstrual 
disorders, caused by disturbance of the HPO system. However, it is well known that in vitro 
studies or analyses using animal models do not always coincide with the effects in humans. 
Therefore, we also present evidence demonstrating the effects of Kampo formulae on 
menstrual disorders in clinical trials. 
3.1 Tokishakuyakusan 
A double-blind study was performed using Tokishakuyakusan to treat primary 
dysmenorrheal (31). As a result, a significant alleviation of dysmenorrhea was observed in 
patients treated with Tokishakuyakusan compared to that of those treated with placebo, 
suggesting that Tokishakuyakusan is effective for treating dysmenorrhea in patients with 
coldness and low daily activity. This study can be recognized as an attempt to define the 
indications for Tokishakuyakusan using the Kampo diagnostic system (i.e., low vigor, 
coldness and blood stasis in patients with dysmenorrheal). Since it is important to reduce 
the use of analgesics for pain relief, continued studies are expected, to determine whether 
Tokishakuyakusan is also effective for patients not responding to analgesics. 
Another clinician has reported an antidysmenorrhea therapy using a cyclic regimen of 
Shakuyakukanzoto and Tokishakuyakusan, in which the herbs are administered alternately 
within the menstrual cycle (32). In 12 dysmenorrhea patients treated with the 
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Shakuyakukanzoto and Tokishakuyakusan cyclic therapy, 9 patients ovulated as 
determined by biphasic changes in basal body temperature patterns, suggesting that the 
“cyclic therapy” can be a conservative antidysmenorrhea therapy for endometriotic and 
adenomyotic patients who desire pregnancy. 
3.2 Keishibukuryogan 
Keishibukuryogan is the most common choice among complementary medicines for 
treatment of menstrual disorders in Japan. This formula is used to improve various signs 
and symptoms of endometriosis without decreasing serum estradiol levels or causing 
menstrual disorders. There is the examination and comparison between the effects of 
Keishibukuryogan and danazol on anti-endometrial humoral immunity in humans (33). 
Absorption tests of nonspecific antibodies using cervical cancer cells or ovarian cancer 
cells demonstrated that endometriotic patients had higher levels of endometrium-specific 
autoantibodies than healthy women without endometriosis. IgM fractions from 
endometriotic patients and healthy women differed in their effect on growth of 
endometrial adenocarcinoma cells. Therapy with Keishibukuryogan but not danazol 
therapy, gradually decreased the tissue-specific anti-endometrial IgM antibody levels, 
indicating that tissue-specific anti-endometrial IgM may be a useful therapeutic marker 
for endometriotic patients treated with Keishibukuryogan and that endometrial tissue-
specific immune disorders play specific roles in the pathogenesis or development of 
endometriosis in humans. 
3.3 Kamishoyosan 
Although Kamishoyosan is a common Kampo formula for menopausal disorders such as 
psychological or vasomotor symptoms, there are few reports demonstrating the clinical 
efficacy of Kamishoyosan for menstrual irregularities (34). 
It has been demonstrated that 30 patients with premenstrual dysphoric disorder (PMDD) 
were treated with Kamishoyosan for six menstrual cycles and 19 patients (63.3%) had 
>50% improvement in the total score on the Hamilton Depression Rating Scale (HAM-D) 
Scale in the late luteal phase, and 14 patients (46.7%) went into remission (35). Regarding 
the mechanism of action of Kamishoyosan, studies were conducted to compare the effects 
on serum cytokine concentrations of paroxetine, a selective serotonin re-uptake inhibitor, 
and kamishoyosan (36, 37). In 76 women with psychological symptoms such as anxiety 
and mild depression as menopausal symptoms, Greene's total scores in both women 
treated with paroxetine and in women treated with kamishoyosan decreased significantly. 
The serum IL-6 concentration in women treated with paroxetine decreased significantly. 
Serum concentrations of IL-8, IL-10, macrophage inflammatory protein (MIP)-1┚ and 
monocyte chemoattractant protein-1 in women treated with paroxetine decreased 
significantly. However, serum IL-6 concentration in women treated with kamishoyosan 
decreased significantly, but other serum concentrations did not change significantly. 
Based on the above findings, a decrease in IL-6 concentration may be involved in the 
action mechanisms of both paroxetine and kamishoyosan in women with psychological 
symptoms. 
In conclusion, Kamishoyosan may be a useful agent to alleviate psychological symptoms in 
menopausal woman, but not for menstrual irregularities. 
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3.4 Unkeito 
Unkeito is one of the agents in which its action on the HPO system was analyzed and 
several clinical trials were previously carried out. There is a representative report 
demonstrating the improvement of gonadotropin and estradiol secretion in either hyper- or 
hypo-functioning anovulatory women (38). In patients with amenorrhea, ovulation occurred 
in 61.3% and 66.7% of patients with first-grade amenorrhea, and in 27.3% and 22.4% of 
patients with second-grade amenorrhea, respectively. In these patients, 8 weeks of treatment 
with Unkeito induced a significant increase in plasma FSH, LH and estradiol levels in 
hyper- (robust) and hypo- (asthenia) functioning patients with first- and second-grade 
amenorrhea. There were no significant differences in the rates of change in these hormones 
between hyper- and hypo-functioning patients. Recently, it has been demonstrated that 
Unkeito increases peripheral blood flow, especially in the lower extrimities, and decreases 
blood flow in the upper body, in contrast, there was no difference in circulation in the 
upper- and lower extremities induced by vitamin E (39). Furthermore, the effects of Unkeito 
on the serum levels of several cytokines have also been reported (40). 
4. The current topics concerning Kampo therapeutic strategy for menstrual 
disorders 
Currently a greater proportion of the women diagnosed with breast cancer develop 
estrogen-deficiency symptoms compared to that in the recent past due to advances in 
approaches to breast cancer treatment (41). All premenopausal breast cancer patients 
receiving chemotherapy are at risk of the developing chemotherapy-induced amenorrhea 
(CIA) (41). In these patients, menopausal symptoms must be more serious than amenorrhea. 
Further, women with ER-positive breast cancers face additional risks and approximately 
60% of cancers are ER-positive (42). These patients are not able to be treated with hormone 
replacement therapy (HRT). Therefore, there are no treatments to control menopausal 
symptoms in premenopausal patients with breast cancer. We have reported that 
Nyoshinsan, a Kampo formula, may be useful and a safe agent to treat estrogen-deficiency 
symptoms in breast cancer survivors, since managing estrogen-deficiency symptoms in 
breast cancer survivors remains problematic (43). 
We considered treatment with Nyoshinsan for 6 premenopausal breast cancer survivors 
from the Department of Breast Surgery in our hospital who consulted the Department of 
Japanese Oriental Medicine postoperatively because of menopausal symptoms. As an 
endpoint, we determined the incidence of postmenopausal symptoms such as hot flashes, 
sweating, anxiety and depression, and measured the severity of these symptoms using a 
visual analogue scale (VAS). In addition, we assessed the serum level of estradiol (E2). Their 
menopausal symptoms were mainly vasomotor symptoms such as hot flashes and sweating, 
and mental symptoms such as sleeping disorder and depression, but not skeletal muscle 
symptoms such as shoulder stiffness. In five of the 6 patients, the Nyoshinsan treatment 
resulted in a noticeable alleviation of menopausal symptoms without adverse effects; one 
patient reported that her symptoms did not change. Changes in the serum levels of E2 are 
shown in Figure 1. The serum E2 levels in five patients did not change, but there was an 
increase in the serum E2 level in one patient, who was successfully treated with Nyoshinsan. 
In this patient, the administration of Nyoshinsan was discontinued and her serum E2 level 
decreased. A representative patient with premenopausal breast cancer who was successfully 
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treated with Nyoshinsan for estrogen-deficiency symptoms that were induced 
postoperatively by adjuvant chemotherapy is also presented (Figure 2). Nyoshinsan resulted 
in the relief of severe menopausal symptoms such as hot flashes, fatigue, and anxiety. 
Furthermore, serum levels of E2 and FSH did not change from the baseline. Nyoshinsan 
may be a useful and safe agent to treat estrogen-deficiency symptoms in breast cancer 
survivors, because managing estrogen-deficiency symptoms in these patients remains 
problematic.  
These observations demonstrate that Kampo formulae may alleviate climacteric symptoms 
by an action that differs from E2-like effects of folk medicines, such as Pueraria mirifica or 
Vitex agnus castus. 
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Fig. 1. Changes in the serum levels of estradiol (E2) during treatment with Nyoshinsan/TJ-
67. In five patients, the E2 level did not change, while one patient showed an increase in the 
serum level of E2. Open circles, patients with noticeable improvement; closed circle, one 
patient without improvement. 
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Fig. 2. Clinical course in representative patient described in the case report. The oral 
administration of Nyoshinsan resulted in the relief of severe menopausal symptoms such as 
hot flashes, fatigue, and anxiety. Serum levels of E2 and follicle-stimulating hormone (FSH) 
did not change from the baseline values. VAS, Visual analogue scale; chemotherapy*, 
cyclophosphamide 300 mg, pirarubicin hydrochloride 45 mg, and 5-fluorouracil 750 mg. 
5. Conclusion 
Actions on the HPO system and the clinical efficacy of traditional herbal medicine are being 
clarified. Traditional herbs possess unique functions that are different from those of pure 
chemical compounds. It has been expected that traditional herbs will become interestingly 
applicable to the treatment of menstrual irregularities, such as amenorrhea.  
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